Similar Items: Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS
- Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database
- Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice
- Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases
- Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system
- Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS)
- Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER